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Abstract: Parkinson’s disease (PD) is caused by loss in nigrostriatal dopaminergic neurons 
and is ranked as the second most common neurodegenerative disorder. Dopamine receptor D3 
is considered as a potential target in drug development against PD because of its lesser side 
effects and higher degree of neuro-protection. One of the prominent therapies currently avail-
able for PD is the use of dopamine agonists which mimic the natural action of dopamine in the 
brain and stimulate dopamine receptors directly. Unfortunately, use of these pharmacological 
therapies such as bromocriptine, apomorphine, and ropinirole provides only temporary relief of 
the disease symptoms and is frequently linked with insomnia, anxiety, depression, and agitation. 
Thus, there is a need for an alternative treatment that not only hinders neurodegeneration, 
but also has few or no side effects. Since the past decade, much attention has been given to 
exploitation of phytochemicals and their use in alternative medicine research. This is because 
plants are a cheap, indispensable, and never ending resource of active compounds that are 
beneficial against various diseases. In the current study, 40 active phytochemicals against PD 
were selected through literature survey. These ligands were docked with dopamine receptor D3 
using AutoDock and AutoDockVina. Binding energies were compared to docking results of drugs 
approved by the US Food and Drug Administration against PD. The compounds were further 
analyzed for their absorption, distribution, metabolism, and excretion-toxicity profile. From 
the study it is concluded that glycyrrhetinic acid and E.resveratroloside are potent compounds 
having high binding energies which should be considered as potential lead compounds for drug 
development against PD.
Keywords: AutoDock, AutoDockVina, molecular docking, parkinson’s disease, glycyrrhetinic 
acid, E.resveratroloside
Introduction
Parkinson’s disease (PD) is the most common form of Parkinsonism. It is a neurodegen-
erative disorder which notably causes rigidity, bradykinesia, tremor, stooped posture, 
dementia, and depression in PD patients. Due to unclear etiology this disease is also 
known as Idiopathic Parkinsonism. But certain factors ie, environmental chemicals, 
drinking water chemistry, pesticide exposure, and rural living are responsible for 
PD.1–3 Moreover, mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes 
are also found to be accompanied by PD.4
Degeneration of nigrostriatal pathway, noradrenergic locus ceruleus, motor 
vagal nucleus, the serotonergic raphe nuclei, cholinergic nucleus basalis of Meynert, 
pedunculopontine nucleus pars compacta, Edinger-Westphal nucleus, and many 
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peptidergic brainstem nuclei are characteristic of PD.5 
However, it is believed that the primary cause of the disease 
is loss in the nigrostriatal dopaminergic neurons, formation 
of intraneuronal, proteinaceous cytoplasmic inclusions called 
Lewy bodies, inability to produce dopamine, mitochondrial 
respiration defect, and oxidative stress. Consequently, 
a striatal dopamine-deficiency syndrome occurs being 
responsible for the classical motor symptoms of PD.6,7
PD is a progressive disorder, affecting one in every 
100 people older than 65 years of age. The symptoms usually 
appear when approximately 60% of the dopamine producing 
neurons are lost.8,9 PD is ranked as the second most common 
neurodegenerative disorder after Alzheimer’s disease.10 
Unfortunately, no therapeutic curative regimen has been 
devised yet.9 One of the most prominent treatments for PD 
is the use of dopamine agonists which mimic the natural 
action of dopamine in the brain and stimulate dopamine 
receptors directly.11 These dopamine agonists will meet the 
dopamine requirement of the brain and help in bringing 
about the restoration of normal functionality of the remaining 
dopaminergic neurons.
Biochemical and electrophysiological data suggest that 
dopamine acts on its very own special dopamine recep-
tors. They show variance in their anatomical localization, 
functional substantiality, and pharmacological importance.12,13 
This is why they are differentiated into five types of dop-
amine receptors (D1–D5). Dopamine receptor D3 (DRD3) 
serves as a potential target for drug development as several 
experimental data suggest that DRD3 agonists are involved 
in neuroprotection and alleviating motor dysfunctions.14 
Furthermore, neuroprotection and neurorestoration are also 
seen in animal models by using DRD3 agonist.15
Dopamine carries out cell cycle modulation in both 
developing and adult brain and DRD3 receptor play a vital 
role in dopaminergic neuronal development. Activation of 
these receptor subtypes leads to propagation of neurogenesis 
in substantia nigra in animal models. Moreover, a persistent 
recovery in the locomotor functions was also seen.16
Drugs with DRD3 receptor proffering behavior, when 
acting on their receptors, causes an increase in production of 
dopamine neurotrophic factor in tissue culture. This factor 
can also be the autotrophic factor for the dopaminergic 
neurons. This protein is oxidant labile, therefore, the drugs 
having DRD3 receptor agonistic activity that results in the 
increase of this protein and also having the antioxidant profile 
will provide a unique therapeutic strategy.17
In early and moderate PD, the dopamine receptor agonists 
have shown effectiveness as symptomatic monotherapy.18 
However, use of current pharmacological therapies such as 
bromocriptine, apomorphine, and ropinirole provides only 
temporary relief of the disease symptoms and is frequently 
linked with insomnia, anxiety, depression, and agitation.19 
Moreover, dose failure or wearing-off effects are common 
and high doses are required to overcome the problem. Usually 
elderly patients are highly sensitive to wearing-off effects.9,20,21 
Memory problems and confusion are associated with anticho-
linergics. Monoamine oxidase inhibitors precipitate many 
side effects when given in combination therapy. Psychiatric 
complications, pathological gambling, and depression is also 
reported with other anti-parkinsonian therapy.22,23 Thus, there 
is a need for an alternative treatment that not only hinders 
neurodegeneration but also has few or no side effects.
Since the past decade much interest has been seen 
in exploitation of phytochemicals. Phytochemicals are 
considered as a potential alternative cure for various 
neurodegenerative diseases including PD. This is because 
plants are a cheap, indispensable, and never ending resource 
of active compounds that are beneficial against various 
diseases. These phytochemicals belong to various classes of 
compounds such as phenolics, alkaloids, terpenoids, lignans 
etc. Several phytochemicals having beneficial affects against 
PD have been reported in literature. Many studies have also 
revealed promising results in decreasing levels of free radicals 
which is a major cause of neurodegeneracy.24–28 Therefore, the 
current study was designed to find potential lead compounds 
from different plants against PD that can be developed into 
commercial drugs.
In this investigation, various phytochemicals active 
against PD were identified through literature survey. They 
were screened through in silico docking analysis to find 
potential lead compounds for PD. The molecular docking 
tools, AutoDock and AutoDockVina (Scripps Research Insti-
tute, La Jolla, CA, USA) were used to dock 40 phytochemi-
cals against DRD3. The ligands were also analyzed for their 
absorption, distribution, metabolism, and excretion-toxicity 
(ADMET) profile. ADMET profile determines the absorp-
tion, distribution, metabolism and excretion efficiency of the 
drug. It also predicts the risk of toxicity upon consumption of 
the compound.29 Lead compounds having impressive phar-
macokinetics and pharmacodynamic properties have a better 
chance to be developed into commercial drugs. In vitro analy-
sis of ADMET properties is usually carried out during the 
end stage of drug development due to which several potent 
compounds fail to achieve drug status. In silico ADMET 
analysis not only decreases the cost of drug designing but 
also skips the risk of rejection of a compound.30
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From the results of the current study it is concluded that 
glycyrrhetinic acid, and E.resveratroloside showed high 
binding energy against dopamine DRD3 when docked with 
AutoDock and AutoDockVina. They also possess a good 
ADMET profile and should be considered potential lead 
compounds for drug development against PD.
Material and methods
Preparation of data set
The three dimensional (3D) structure of DRD3 was retrieved 
from the protein data bank (PDB ID: 3PBL with a resolution 
[Å]: 2.89, R-Value: 0.245).31 This structure was complexed 
with dopamine 2/dopamine 3 selective antagonist eticlopride 
(3-chloro-5-ethyl-N-{[(2S)-1-ethylpyrrolidin-2-yl] methyl}-
6-hydroxy-2-ethoxybenzamide). Phytochemicals for the 
study were collected after extensive literature survey. All 
phytochemicals included in this study have been reported to be 
active against PD after in vitro analysis in different studies.32–34 
Their respective structures were obtained from the publicly 
available database, Pubchem.35 Selected phytochemicals were 
sorted according to Lipinski’s rule. Only those structures were 
selected for docking that strictly followed the Lipinski’s rule 
(details for all selected compounds are given in Table S1).
Protein and ligand optimization
In order to figure out the equilibrium configuration of 
biomolecules and solids, energy optimization methods were 
used. Crystal structure of DRD3 was further processed for 
molecular docking studies. For this, all the hetero-atoms 
and water molecules were removed from protein structure 
followed by energy minimization in order to remove all the 
bad steric clashes using the UCSF Chimera (Resource for 
Biocomputing, Visualization, and Informatics, University of 
California San Francisco, San Francisco, CA, USA) for 1,000 
steepest descent steps at root-mean-square gradient of 0.02 
with an update interval of 10 and using AMBER ff12SB force 
field.36,37 The structure-data file two dimensional structures of 
phytochemicals were converted into MOL 3D structure using 
Open babel. It was followed by energy minimization through 
Hyperchem’s (Gainesville, FL, USA) MM+ force field.
Determination of binding site
Binding sites of proteins are often located in the structural 
pockets and cavities which show high affinity for selective 
drugs. The binding site of DRD3 was revealed by knowl-
edge based studies.31 The binding residues were further 
inspected by using Computed Atlas of Surface Topography 
of Proteins (CASTp) server and Q-Site Finder.38,39 CASTp 
server uses the weighted Delaunay triangulation and the 
alpha complex for shape measurements. It provides iden-
tification and measurements of surface accessible pockets 
as well as interior inaccessible cavities, for proteins and 
other molecules. It measures analytically the area and 
volume of each pocket and cavity, both in solvent acces-
sible surface and molecular surface. Q-Site Finder uses the 
interaction energy between the protein and a simple van 
der Waals probe to locate energetically favorable binding 
sites. Pocket Finder is another tool used for analysis of 
binding sites of a protein and uses Ligsite algorithm. Lig-
site algorithm is designed to heuristically search protein 
for probable interaction of ligand and generate profiles of 
best active sites.40
computational docking strategy between 
DrD3 and phytochemicals
All computational docking studies were carried out using 
AutoDock 4.0 and AutoDockVina41 installed in a single 
machine running on an OptiPlex 980 (Dell, Round Rock, 
TX, USA), Corei3-550/3.2 card GT-203 (Intel, Santa 
Clara, CA, USA) with LINUX (Ubuntu, Canonical Group 
Limited, London, UK) as an operating system.42 Automated 
dockings were performed using the AutoDock 4.0 tool to 
locate the proper binding orientations and conformations 
of various ligands. For DRD3 binding precisely, ligands 
and receptors were subjected to polar hydrogen atoms 
and Gasteiger charges and all torsions were permissible 
to rotate while docking. Grid maps were created using 
the AutoGrid program (Scripps Research Institute). The 
dimensions of the grid were defined with points separated 
by 0.375A°. A random approach of starting positions, 
torsions, and orientations was applied for all ligands and 
default settings of the AutoDock program were used for 
translation, quaternion, and torsion steps. Minimization was 
done by using default parameters by Lamarckian genetic 
algorithm. The standard docking protocol consisted of 100 
runs with an initial population of 150 randomly placed 
samples for rigid and flexible ligand docking with energy 
evaluations 2.5×105, mutation rate 0.02, crossover rate of 
0.80, maximum number of 27,000 iterations, and an elitism 
value of 1 used as standard. Root-mean-square tolerance of 
1.0A° was used for cluster analysis on the docked results. 
The cluster having a higher number of confirmation and 
a low binding energy was selected as the docked pose of 
the respective ligand; the binding energy of each cluster 
being the mean binding energy of sum of confirmations 
present in the cluster.
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AutoDockVina was employed to find the most probable 
ligands for target protein, and ligands were docked at DRD3. 
For this purpose, blind docking was performed by covering 
the whole protein under the grid to detect if there is any other 
binding site available other than provided by PDB crystal 
structure. Gasteiger charges were added to convert protein 
and all ligand molecules into PDBQT files. Protein was 
prepared with identical steps used for AutoDock 4 docking 
experiment. All ligands were docked by AutoDockVina and 
results were further analyzed in conjunction with results by 
AutoDock tools using Chimera. Potential ligands were sorted 
on the basis of making highest interactions with binding 
pocket and minimum binding energy values. The comparison 
of results from both of the tools was considered based on the 
minimum binding energy. 
Drug-likeness and aDMeT analysis
In-silico analysis of drug likeness was performed in order to 
check the potential DRD3 ligands for their ability to follow 
Lipinski’s rule of five.43 This was done by uploading ligands 
to Mcule,44 Molsoft, and Molinspiration server (http://www.
molinspiration.com/cgi-bin/properties) for calculation of 
their molecular properties (Table 1). The chemical structures 
of potential ligands were submitted to admetSAR (http://
lmmd.ecust.edu.cn:8000/) server for in-silico prediction of 
ADME-Tox (absorption, distribution, metabolism, excretion 
and toxicity) properties.45 Furthermore, online server Osiris 
Property Explorer (http://www.organic-chemistry.org/prog/
peo/) was used to predict the tumorigenic, reproductive, and 
mutagenic risks (Table 2).
Results and discussion
Molecular docking enables a scientist to virtually screen 
a number of candidate compounds based on their binding 
ability and binding orientation with a target molecule. It 
also allows one to select compounds with strong affinity for 
the target site. In the current study, phytochemicals have 
been docked in silico with DRD3 to find the best dopamine 
agonist candidates that can hinder neurodegeneration in PD. 
Saponins, flavonoids, alkaloids, lignin, and diarylheptanoids 
have shown high binding energy when docked with DRD3. 
Specifically, glycyrrhetinic acid (-7.11 and -12.7 kcal/mol) 
and E.resveratroloside (-7.03 and -11.7 kcal/mol) have 
shown stronger binding at the receptor’s binding site in exper-
iments when analyzed using AutoDock and AutoDockVina 
respectively (Tables 3 and 4).
Binding residues’ analysis
We performed binding site analysis of our protein through 
CASTp and Pocket Finder. CASTp results were analyzed 
through special plugin of Chimera for better understanding 
of active site. It was observed that the pockets provided by 
CASTp were similar to those found in DRD3 crystal struc-
ture. It also provided other pockets with measurements. An 
in-depth analysis of pockets demonstrated that the pocket hav-
ing residues similar to those found in DRD3 crystal structure 
could be the most potent active site. The results of CASTp 
were also compared with Pocket Finder results. The pockets 
generated through Pocket Finder were analyzed and compared 
with crystal structure of DRD3. It demonstrated residues 
already observed in crystal structure and also some additional 
potent active sites’ residues involved in the binding site of 
protein are shown in (Figure 1). The crystal structure and 
computational analysis of binding site support that Asp110, 
Ile183, Ser192, Phe346, His349, Thr369, Tyr373 act as active 
site residues in 3D crystal structure of human DRD3.31
Molecular interactions
The location of drug binding is a crucial site for designing 
viable drug molecules against any disease. Therefore, the 
Table 1 Lipinski’s rule of five drug-likeness properties of potential compounds by using Molsoft, Mcule, and Molinspiration web-servers
Ligand Glycyrrhetinic acid E.resveratroloside Genkwanin Protopine Naringenin Pergolide Magnolol
MW 470 390 284.26 353.36 272.25 341.4 266.3
logP 5.64 1.99 2.87 2.49 2.5 4.2 4.22
TPsa 74.3 138.5 79 57.23 86 44.3 40.4
reactivity 136 100 78 97 71.5 101.6 84.13
n On 4 8 5 6 5 2 2
n Ohnh 2 5 2 0 3 1 2
n rotb 1 5 2 0 1 1 5
n atoms 80 50 33 45 32 48 38
n violations 0 0 0 0 0 0 0
Abbreviations: MW, molecular weight; LogP, lipophilic efficiency; n ON, hydrogen bond acceptor; n OHNH, number of hydrogen bond donor; TPSA, topological polar 
surface area; n violations, number of Lipinski’s rule of five violations; n rotb, number of rotatable bonds; n atoms, number of atoms.
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binding site was further confirmed with the help of CASTp 
and Pocket Finder. It was observed that DRD3 crystal 
structure shows valuable information of interacting resi-
dues, located in the binding pocket such as Asp110, Ile183, 
Ser192, Phe346, His349, Thr369, and Tyr373, respectively 
which play an important role in phytochemical binding. 
Our docking result with phytochemicals showed that many 
potential compounds were actively involved in hydrogen 
bonding with five polar residues such as, aspartic acid, serine, 
histidine, threonine, and tyrosine. Other crucial hydrophobic 
interactions were also found to exist that increase binding 
of phytochemicals with protein binding pocket (Table 5). 
In the docking results however, Thr369 was frequently 
seen to be a common residue amongst phytochemicals with 
high binding energies in the docking results. This is seen 
to be followed by Tyr373, Asp110, and Ile183 residues 
which also occur frequently. Thr369 and Tyr373 were also 
found to be common amongst the binding site of synthetic 
drugs used in the study namely bromocriptine, apomor-
phine, and ropinirole. Further, docking studies revealed 
the results with a binding score up to a maximum of -7.11 
kcal/mol, which is higher than the binding energy range of 
Table 2 aDMeT properties of potential DrD3 compounds predicted from admetsar and Osiris Property explorer 
ADMET Glycyrrhetinic 
acid
E.resveratroloside Genkwanin Protopine Naringenin Pergolide Magnolol
BBB + + - + + + +
human intestinal  
absorption
+ + + + + + +
caco-2 permeable +  - + + + + +
aqueous solubility -4.09 -2.45 -3.17 -4.72 -2.64 -4.05 -4.53
P-gp        
substrate + + + + + + -
inhibitor - - - - - - -
cYP450 substrate        
cYP450 2c9 - - - - - - -
cYP450 2D6 - - - + - - -
cYP450 3a4 + - - + - - -
cYP450 inhibitor        
cYP450 1a2 - - + + + + +
cYP450 2c9 - - + - + - +
cYP450 2D6 - - - + - + -
cYP450 2c19 - - + + + - +
cYP450 3a4 - - + - + - +
cYP iP low low high low high low high
rOcT - - - - - + -
herg inhibition        
herg-i Weak Weak Weak Weak Weak Weak Weak
herg-ii - - - - - + -
aMes Toxicity - - + + - - -
Mutagenic - - - - + - -
Tumorigenic - - - - - - -
reproductive  
effective
- + - - - + -
carcinogens - - - - - - -
Biodegradation - + - + - - -
irritant - - - - - - -
raT, lD50 mol/kg 2.3773 2.1382 2.5626 2.3873 3.511 2.8857 2.0106
FT, plc50 mol/kg high, 0.6994 high, 0.9172 high, 0.5913 high, 1.0291 high, 0.7217 high, 1.1094 high, 0.14
TPT, pigl50 mol/kg high, 0.9506 high, 0.3495 high, 1.1785 high, 0.4287 high, 0.6757 high, 0.7614 high, 1.9675
Notes: raT, lD50 is the lethal dosage of drug when tested on mice; FT (fish toxicity) is environmental risk assessment of drug based on fish and TPT (Tetrahymena pyriformis 
toxicity) as environmental indicators.
Abbreviations: aDMeT, absorption, distribution, metabolism, and excretion-toxicity; DrD3, dopamine receptor D3; BBB, blood–brain barrier penetration; hia, human intestinal 
absorption; caco-2, caco-2 permeability; cYP, cytochrome P; iP, inhibitory promiscuity; rOcT, renal organic cation transportation; herg, human ether-a-go-go-related genes 
inhibition; raT, rat acute toxicity; P-gp, permeability glycoprotein; plc50, lethal concentration, 50%; pigl50, blood glucose; lD50, lethal dose, 50%; +, present; -, not present.
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US Food and Drug Administration (FDA) approved drugs 
(-4.88 to -5.81 kcal/mol). Analyses showed that the top 
nine compounds with considerable high affinity for DRD3 
share a somewhat common active site. After careful obser-
vation of molecular interactions, it was recognized that the 
H-bond interactions with Thr369 and Tyr373 were reported 
in many phytochemicals that were showing binding ener-
gies greater than -6.00 kcal/mol, such as, glycyrrhetinic 
acid, E.resveratroloside, genkwanin, protopine, naringenin, 
pergolide, magnolol, honokiol, and hirsutanone. However, 
glycyrrhetinic acid and E.resveratroloside neatly fit into the 
binding pocket of DRD3 hence (Figure 1), justifying their 
high binding values as compared to other compounds.
comparative studies with autoDockVina
The present comparative docking of phytochemicals with 
DRD3 using two different tools confirmed that AutoDockVina 
showed high binding energies as compared to AutoDock 
Tool. This is due to the fact that Vina uses a gradient opti-
mization method in its local optimization procedure and has 
better accuracy of the binding mode prediction. Our results 
suggested that binding energy between ligand and target 
molecule has been enhanced in AutoDockVina. Binding 
energies calculated using AutoDock tool for glycyrrhetinic 
acid, E.resveratroloside, genkwanin, protopine, naringenin, 
pergolide, and magnolol were in the range (-6.14 to -7.11 
kcal/mol). However, this range of binding energy increased 
(-8.3 to -12.7 kcal/mol) in the case of AutoDockVina and 
showed strong binding (Table 6). A varying trend of binding 
energies was seen amongst the phytochemicals docked in 
both tools. Flavonoids were observed to rank higher when 
docked in AutoDockVina as compared to AutoDock where 
a mixed trend of saponins, lignins, phenols, and alkaloids 
was seen to rank high. 
Table 4 AutoDockVina estimated binding energy (G) and different molecular interactions of phytochemicals in the binding site 
of dopamine receptor D3
Ligands–PubChem ID Binding energy 
G (kcal/mol)
Binding site  
interacting residues
No of H-bonds 
interactions
No of hydrophobic 
interactions 
Total no 
of bonds
glycyrrhetinic acid-10114 -12.7 Tyr373, Thr369 2 10 12
e.resveratroloside-6481477 -11.7 Thr369, Phe345, his349, ile183, asp110, 
ser192
2 6 8
curcumin-969516 -10.9 ile183, his349, Phe345, Thr369, asp110 0 11 11
hirsutanonol-9928190 -10.9 Phe345, ile183, ser192 0 8 8
glabridin_124052 -10.7 ser192, Phe345, asp110, ile183 2 8 10
alloin-313325 -10.6 ile183, Tyr373 0 8 8
Diacerein-26248 -10.3 Tyr373, Thr369 3 10 13
Bromocriptine-31101 -7.9 Ser192, Thr369 0 10 10
Apomorphine-6005 -7.7 Asp110, Thr369 1 9 10
Ropinirole-5095 -7.4 Ser192, Phe346, Thr369, Tyr373 0 5 5
Note: The bold font corresponds to Us Food and Drug administration approved drugs. 
Abbreviation: no, number.
Table 3 AutoDock estimated free energies of binding (G) of phytochemicals in the active site of dopamine receptor D3
Ligands–PubChem ID Inhibition  
constant (µM)
Intermolecular 
energy (kcal/mol)
Binding energy 
G (kcal/mol)
Docking energy 
(kcal/mol)
glycyrrhetinic acid-10114 6.11 -8.65 -7.11 -12.7
e.resveratroloside-6481477 11.65 -8.34 -7.03 -11.7
genkwanin-5281617 20.64 -6.95 -6.89 -9.5
Protopine-4970 17.94 -6.67 -6.59 -9.6
naringenin-439246 48.83 -7.07 -6.21 -9.8
Pergolide-47811 41.34 -7.05 -6.15 -8.3
Magnolol-72300 31.77 -8.16 -6.14 -9.1
Bromocriptine-31101 15.36 -7.71 -5.81 -8.7
Apomorphine-6005 11.99 -6.81 -5.71 -8.3
Ropinirole-5095 263.84 -6.76 -4.88 -8
Notes: The table demonstrates a comparison against our computationally selected drugs with US Food and Drug Administration (FDA) drugs that are currently being used 
in market. The bold font corresponds to FDa approved drugs.
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Table 5 Phytochemicals displaying different types of molecular interactions with dopamine receptor D3
Ligands–PubChem ID Binding site  
interacting residues
No of  
H-bonds 
interactions
No of 
hydrophobic 
interactions 
No of polar 
interactions 
No of 
non-polar 
interactions
Total no 
of bonds
glycyrrhetinic acid-10114 Tyr373, Thr369 2 11 3 4 20
e.resveratroloside-6481477 asp110, ile183, ser192, his349, Thr369, 
Tyr373
2 6 4 3 15
genkwanin-5281617 asp110, ile183, ser192, his349, Tyr373 1 10 2 5 18
Protopine-4970 Phe346, Thr369 1 9 2 8 20
naringenin-439246 asp110, ile183, ser192, his349 0 8 5 3 16
Pergolide-47811 ile183, his349, Thr369, Tyr373 1 9 4 2 16
Magnolol-72300 asp110, ile183, ser192, Phe346, Thr369 1 10 3 2 16
Bromocriptine-31101 His349, Thr369 1 11 2 3 17
Apomorphine-6005 Asp110, Thr369, Tyr373 3 9 3 4 19
Ropinirole-5095 Asp110, Ile183, Ser192, Phe346,  
Thr369, Tyr373
1 12 1 5 19
Note: The bold font corresponds to Us Food and Drug administration approved drugs. 
Abbreviation: no, number.
Figure 1 Molecular surface representation of binding pocket of dopamine receptor D3. 
Notes: Binding pocket residues within the deep groove are labeled as black text and signified with brown surface. Ligands (stick view) are shown with colors as evaluated by 
AutoDock 4.2 (in pink) and AutoDockVina (in sky blue) in both software programs. (A) Confirmation of E.resveratroloside; (B) confirmation of glycyrrhetinic acid.
Both AutoDock 4.0 and AutoDockVina use Monte-
Carlo algorithm. In our experiment, we tried to find the 
most probable small molecules that may act against DRD3 
to cure PD. Docking results were sorted and ranked on the 
basis of their binding energy values. The first ten compounds 
from each of AutoDock 4.0 and AutoDockVina results were 
chosen for further analysis. The comparison showed that 
four compounds were common that have higher binding 
energy values for DRD3. Except binding energy values, 
these four compounds were found to make more interactions 
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with DRD3. These compounds were also compared with 
FDA approved drugs. The comparison with drugs showed 
that the most potent compounds, glycyrrhetinic acid and 
E.resveratroloside, showed the highest binding energy values 
when analyzed using both software and also presented strong 
interactions with DRD3 (Table 6).
Although differing in precision and binding affinities, 
glycyrrhetinic acid and E.resveratroloside were popularly 
recognized as lead compounds in both the software programs 
(Figure 1A, B). Both ligands were found to bind inside a 
deep groove surrounded by seven amino acid residues with 
considerably high binding energy values regardless of the tool 
being used. Figures 1 and 2 illustrate a detailed interaction of 
glycyrrhetinic acid and E.resveratroloside with DRD3 inside 
a deep groove.
aDMeT analysis
The molecular structures of potential ligands, glycyrrhetinic 
acid, E.resveratroloside, genkwanin, protopine, naringenin, 
pergolide, and magnolol were submitted to Mcule, Molsoft, 
Molinspiration, admetSAR, and Osiris property servers to 
determine their different properties including drug likeness 
and ADMET properties. All these potential compounds 
followed the Lipinski’s rule of five without any viola-
tion with respect to an octanol-water partition coefficient 
(LogP 5), molecular weight (500 KDa), number of 
H-bond donors (5), number of H-bond acceptors (10), 
molecular refractivity (40–130) as tabulated in Table 1. In 
ADMET assessment, different pharmacokinetic and phar-
macodynamic parameters were considered such as aqueous 
solubility,46 human intestinal absorption,47 blood–brain 
barrier penetration, Caco-2 permeability, cytochrome P450 
inhibition,48 cytochrome P (CYP) inhibitory promiscuity, 
renal organic cation transportation, human ether-a-go-go-
related genes inhibition, rat acute toxicity, fish toxicity, Tet-
rahymena pyriformis toxicity, AMES toxicity, tumorigenic, 
reproductive, and mutagenic risks. The results have been 
summarized in Table 2. The bioavailability and toxicity risks 
of the potential compounds were predicted based on their 
ADMET properties. Interestingly, the analysis performed 
on admetSAR and Osiris property explorer revealed that 
only glycyrrhetinic acid, E.resveratroloside, and pergolide 
had no substantial ADMET properties that could cause 
adverse effects in humans. Whereas genkwanin, naringenin, 
and magnolol have the potential to show adverse effects 
in recipients. The analysis displays high CYP inhibitory 
promiscuity, as they inhibit most of the cytochrome P450 
isoforms containing CYP450 1A2, 2C9, 2C19, and 3A4.49 
The cytochrome P450 superfamily shows a significant 
role in metabolizing the drug and its clearance in the liver. 
Therefore, the inhibition of cytochrome P450 isoforms 
might affect the drug metabolism and elevate the toxicity 
level.50 The analysis also inferred that, except pergolide, 
none of the potential compounds were potential compounds 
of the human ether-a-go-go-related gene. In fact, other 
than pergolide, none of the compounds were carcinogenic, 
tumorigenic or irritant to humans. Most interestingly, it was 
noticed that both lead compounds, glycyrrhetinic acid and 
E.resveratroloside, indicated the most favorable ADMET 
properties. They were seen to show negative results for 
AMES toxicity, carcinogenicity, mutagenicity, and tumori-
genicity. Both compounds also showed promising human 
Table 6 Comparison of estimated binding energies (G) of first ten compounds from each of AutoDock 4.0 and AutoDockVina
AutoDock 4 AutoDockVina
Ligands–PubChem ID AutoDock 4 binding 
energy G (kcal/mol)
Ligands–PubChem ID AutoDockVina binding 
energy G (kcal/mol)
Glycyrrhetinic acid-10114 -7.11 Glycyrrhetinic acid-10114 -12.7
E.resveratroloside-6481477 -7.03 E.resveratroloside-6481477 -11.7
genkwanin-5281617 -6.89 curcumin-969516 -10.9
Protopine-4970 -6.59 hirsutanonol-9928190 -10.9
naringenin-439246 -6.21 glabridin_124052 -10.7
Pergolide-47811 -6.15 alloin-313325 -10.6
Magnolol-72300 -6.14 Diacerein-26248 -10.3
honokiol-72303 -6.04 Hesperetin-72281 -10.2
Hirsutanone-637394 -6.01 Hirsutanone-637394 -10.1
Hesperetin-72281 -6.01 luteolin-5280445 -10.1
Bromocriptine-31101 -5.81 Bromocriptine-31101 -7.9
Apomorphine-6005 -5.71 Apomorphine-6005 -7.7
Ropinirole-5095 -4.88 Ropinirole-5095 -7.4
Note: The bold font corresponds to Us Food and Drug administration approved drugs.
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intestinal absorption, blood–brain barrier ability and solu-
bility, and potential non-inhibitor of CYP450 1A2, 2C9, 
2D6, 2C19, 3A4, as these factors help in metabolizing and 
in flushing out the drugs from the body.49
Conclusion
The ascription of all the unique benefits to the DRD3 agonists 
is currently under investigation and there is a possibility of 
an increase in therapeutic index of regimes using these ago-
nists. However, an increase in potency of drugs is evident 
using DRD3 agonists. Anti-parkinsonian efficacy has also 
dramatically increased using DRD3 agonists via the auto-
trophic factor pathway. A profound therapeutic leap seems 
to be promising using these agonists.
In the current study 40 phytochemicals were retrieved 
from a literature survey and docked using AutoDock and 
AutoDockVina against DRD3 to find potent lead compounds 
for PD treatment. The compounds were also assessed for 
their ADMET properties. From this study it can be concluded 
that Thr369, Tyr373, Asp110, and Ile183 are likely target 
sites for designing drugs against PD. Also, glycyrrhetinic 
acid and E.resveratroloside have been identified as potential 
compounds that should be scrutinized for use against PD 
as potent drugs. These two compounds have shown strong 
binding affinity for DRD3. The ligand-receptor complex 
of glycyrrhetinic acid and E.resveratroloside shows strong 
hydrogen bonding as well as van der Waals forces between 
the two. It is apparent that this bonding firmly grips the 
Figure 2 Dopamine receptor D3 and ligands’ interactions. 
Notes: The seven binding residues of receptor are displayed (stick view) and ligands are represented in mesh form as evaluated by AutoDock 4.2 (in pink) and AutoDockVina 
(in sky blue). Binding residues are colored as: Asp110 in orange, Ile183 in green, Ser192 in red, Phe346 in cyan, His349 in magenta, Thr369 in yellow, and Tyr373 in blue. 
(A) top view, (B) back view, and (C) front view of E.resveratroloside. (D) Top view, (E) back view, and (F) front view of glycyrrhetinic acid.
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ligand into the receptor’s binding pocket. We performed an 
in-depth analysis of protein binding site and comparative 
docking to ascertain best docked poses of ligands. The best 
ligands we found were based on making high interactions 
with protein residues and had minimum energy values. The 
ligand docking results were compared with docking results 
of FDA approved drugs. Interestingly, a wide difference in 
affinity values was observed between glycyrrhetinic acid, 
E.resveratroloside, and FDA approved drugs. A consensus 
of result was observed when docking results of AutoDock 
and AutoDockVina were evaluated. Further, glycyrrhetinic 
acid and E.resveratroloside also exhibited good ADMET 
profiles and can be considered safe for development into a 
commercial drug. These results are certainly enlightening that 
glycyrrhetinic acid and E.resveratroloside can be considered 
as a template for future drug designing against PD. 
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Supplementary material
Table S1 Molecular properties of compounds under study
Ligands name–PubChem ID Molecular weight XLog3 H-bond donor H-bond acceptor Molecular formula
glycyrrhetinic acid-10114 470.6838 [g/mol] 6.4 2 4 c30h46O4
e.resveratroloside-6481477 406.38328 [g/mol] 0.2 5 8 c20h22O9
genkwanin-5281617 284.26348 [g/mol] 2.1 2 5 c16h12O5
Protopine-4970 353.36856 [g/mol] 2.8 0 6 c20h19nO5
naringenin-439246 272.25278 [g/mol] 2.4 3 5 c15h12O5
Pergolide-47811 314.48814 [g/mol] 4.2 1 2 c19h26n2s
Magnolol-72300 266.33432 [g/mol] 5 2 2 c18h18O2
honokiol-72303 266.33432 [g/mol] 5 2 2 c18h18O2
hirsutanone-637394 328.3591 [g/mol] 3.1 4 5 c19h20O5
hesperetin-72281 302.27876 [g/mol] 2.4 3 6 c16h14O6
Bromocriptine-31101 654.5945 [g/mol] 3.8 3 6 c32h40Brn5O5
Apomorphine-6005 267.32238 [g/mol] 2.3 2 3 c17h17nO2
glabridin_124052 324.3704 [g/mol] 3.9 2 4 c20h20O4
imperatorin-10212 270.27996 [g/mol] 3.4 0 4 c16h14O4
apigenin-5280443 270.2369 [g/mol] 1.7 3 5 c15h10O5
luteolin-5280445 286.2363 [g/mol] 1.4 4 6 c15h10O6
lisuride-28864 338.44664 [g/mol] 2.7 2 2 c20h26n4O
Polydatin-5281718 390.38388 [g/mol] 1.7 6 8 c20h22O8
emodin_3220 270.2369 [g/mol] 2.7 3 5 c15h10O5
Diacerein-26248 368.29378 [g/mol] 1.9 1 8 c19h12O8
rhein-10168 284.22042 [g/mol] 2.2 3 6 c15h8O6
coumarins_323 146.14274 [g/mol] 1.4 0 2 c9h6O2
hirsutanonol-9928190 346.37438 [g/mol] 2 5 6 c19h22O6
Ropinirole-5095 260.37456 [g/mol] 2.7 1 2 c16h24n2O
Kaempferol_5280863 286.2363 [g/mol] 1.9 4 6 c15h10O6
genistein_5280961 270.2369 [g/mol] 2.7 3 5 c15h10O5
elemicin-10248 208.25364 [g/mol] 2.5 0 3 c12h16O3
Pelargonidin-440832 271.24484 [g/mol] 1.2 4 4 c15h11O5
+
Oregonin-14707658 478.489 [g/mol] 0.5 7 10 c24h30O10
herniarin-10748 176.16872 [g/mol] 1.9 0 3 c10h8O3
Quercetin_5280343 302.2357 [g/mol] 1.5 5 7 c15h10O7
isoliquiritigenin_638278 256.25338 [g/mol] 3.2 3 4 c15h12O4
arecoline-2230 155.19432 [g/mol] 0.3 0 3 c8h13nO2
isohamnetin_5281654 316.26228 [g/mol] 1.9 4 7 c16h12O7
Pilocarpine_5910 208.25694 [g/mol] 1.1 0 3 c11h16n2O2
resveratrol-445154 228.24328 [g/mol] 3.1 3 3 c14h12O3
catechin-9064 290.26806 [g/mol] 0.4 5 6 c15h14O6
curcumin-969516 368.3799 [g/mol] 3.2 2 6 c21h20O6
Zingerone_31211 194.22706 [g/mol] 0.8 1 3 c11h14O3
Myricetin_5281672 318.2351 [g/mol] 1.2 6 8 c15h10O8
asarone-636822 208.25364 [g/mol] 3 0 3 c12h16O3
alloin-313325 418.39398 [g/mol] -0.1 7 9 c21h22O9
Mannitol_6251 182.17176 [g/mol] -3.1 6 6 c6h14O6
Note: The bold font corresponds to Us Food and Drug administration approved drugs.
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